Nurix Therapeutics $160.4 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered follow-on offering of 5,175,000 shares of common stock of Nurix Therapeutics, Inc., including the full exercise by the underwriters of their option to purchase additional shares of common stock. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”
Based in San Francisco, California, Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders.
The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Jonathan Bye and Sherry Tan. The intellectual property and technology transactions team included partner David R. Bauer and associate Marisa Elena Bannon. The tax team included partner Michael Farber and associate Daniel L. Jose. Counsel Marcie A. Goldstein provided FINRA advice. Associate Allison Gunther provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.